Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Ondansetron: a new entity in emesis control.

¹Department of Pharmaceutical Services, Emory University Hospital, Atlanta, GA 30322.

DICP : the Annals of Pharmacotherapy

|November 1, 1990

Summary

This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

A genomic case study of mixed fibrolamellar hepatocellular carcinoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Same author

Effectiveness of a group opt-in session on uptake and graduation rates for pulmonary rehabilitation.

Chronic respiratory disease·2010

Same author

Genomics. Genome project standards in a new era of sequencing.

Science (New York, N.Y.)·2009

Same author

Surveying Saccharomyces genomes to identify functional elements by comparative DNA sequence analysis.

Genome research·2001

Same author

Office-based surgery and cost avoidance in an obstetrics and gynecology residency program.

The American journal of managed care·2000

Same author

Sequence and analysis of chromosome 4 of the plant Arabidopsis thaliana.

Nature·2000

Same journal

Eradication of methicillin-resistant Staphylococcus aureus vaginitis with mupirocin.

DICP : the annals of pharmacotherapy·1991

Same journal

Ketorolac formulary restriction and usage evaluation.

DICP : the annals of pharmacotherapy·1991

Same journal

Oral vancomycin-induced rash: case report and review of the literature.

DICP : the annals of pharmacotherapy·1991

Same journal

Imipenem/cilastatin drug utilization evaluation in a large community hospital.

DICP : the annals of pharmacotherapy·1991

Same journal

Pharmacist involvement in Society of Critical Care Medicine.

DICP : the annals of pharmacotherapy·1991

Same journal

Early anticoagulation therapy in deep vein thrombosis.

DICP : the annals of pharmacotherapy·1991

See all related articles

Ondansetron, a serotonin antagonist, effectively reduces chemotherapy-induced nausea and vomiting. This investigational antiemetic shows promise with fewer side effects than current treatments.

Area of Science:

Oncology
Pharmacology
Gastroenterology

Background:

Chemotherapy often causes severe nausea and vomiting.
Existing antiemetics target dopamine and cholinergic receptors but have significant side effects.
Serotonin receptor blockade is a newer therapeutic approach.

Purpose of the Study:

To evaluate the effectiveness and tolerability of ondansetron for chemotherapy-induced emesis.
To compare ondansetron's side effect profile with existing antiemetic therapies.

Main Methods:

Ondansetron, an investigational serotonin antagonist, was studied for its antiemetic properties.
Effectiveness in combating cancer chemotherapy-induced emesis was documented.
Tolerability and adverse effects were assessed.

Related Experiment Videos

Main Results:

Ondansetron demonstrated effectiveness in treating chemotherapy-induced nausea and vomiting.
The agent was generally well tolerated, with headaches and transient liver enzyme increases as potential side effects.
Notably, no extrapyramidal toxicities were reported with ondansetron.

Conclusions:

Ondansetron is a promising antiemetic for patients undergoing chemotherapy.
It offers a potentially improved safety profile compared to current therapies.
Further research is necessary to fully establish ondansetron's role in antiemetic treatment.